Baker Bros. Advisors Lp bought $1.0M of Entrada Therapeutics (TRDA)
Executed Nov 10 2025, disclosed Nov 12 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 12 2025), the stock returned +41.1% (delay-adjusted); from the execution session (Nov 10 2025), +53.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Baker Bros. Advisors Lp (Other) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 1 sale), most often in Celcuity Inc. (CELC). Across 4 priced purchase filings, the average 21-session return was +14.0% from execution and +7.3% from disclosure (delay-adjusted; derived). The largest single filing was $317.8M of CELC (3,100,000 sh across 2 lots, as filed), executed Jul 14.
Healthcare · Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new c…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→26,468 sh across 2 lots
Exec Nov 20 2025
Filed Nov 24 2025 · 4:09 PM ET